Physician
Emergency Medicine
Dr. David C. Laux, MD
|
|
Give Review
David C. Laux, MD works in the field of Emergency Medicine. David C. Laux is also published. He has 42 publications published. The lastest publication: "A Salmonella typhimurium mutant unable to utilize fatty acids and citrate is avirulent and immunogenic in mice.' David Laux accepts Medicare payments and is registered with Medicare.gov.
Publications
- Comparison of carbon nutrition for pathogenic and commensal Escherichia coli strains in the mouse intestine.
- L-fucose stimulates utilization of D-ribose by Escherichia coli MG1655 DeltafucAO and E. coli Nissle 1917 DeltafucAO mutants in the mouse intestine and in M9 minimal m...
- Role of motility and the flhDC Operon in Escherichia coli MG1655 colonization of the mouse intestine.
- Role of gluconeogenesis and the tricarboxylic acid cycle in the virulence of Salmonella enterica serovar Typhimurium in BALB/c mice.
- Carbon nutrition of Escherichia coli in the mouse intestine.
- Glycolytic and gluconeogenic growth of Escherichia coli O157:H7 (EDL933) and E. coli K-12 (MG1655) in the mouse intestine.
- Immune recognition of human Hsp60 by Lyme disease patient sera.
- Affinity purification of Hydra glutathione binding proteins.
- The effect of plasmid gene expression on the colonizing ability of E. coli HS in mice.
- Radiochemical method for evaluating the effect of antibiotics on Escherichia coli biofilms.
- E. coli colonization of the mammalian colon: understanding the process.
- Relative colonizing abilities of human fecal and K 12 strains of Escherichia coli in the large intestines of streptomycin-treated mice.
- Bacterial adhesion to and penetration of intestinal mucus in vitro.
- Specific phospholipids enhance the activity of beta-lactam antibiotics against Pseudomonas aeruginosa.
- Stimulation of Escherichia coli F-18Col- type-1 fimbriae synthesis by leuX.
- Characterization of the heat shock response and identification of heat shock protein antigens of Borrelia burgdorferi.
- Altered colonizing ability for mouse large intestine of a surface mutant of a human faecal isolate of Escherichia coli.
- Identification and characterization of mouse small intestine mucosal receptors for Escherichia coli K-12(K88ab).
- Isolation and characterization of an attenuated strain of Pseudomonas aeruginosa AC869, a 3,5-dichlorobenzoate degrader.
- Relationship between the mouse colonizing ability of a human fecal Escherichia coli strain and its ability to bind a specific mouse colonic mucous gel protein.
- Adhesion of a human fecal Escherichia coli strain to mouse colonic mucus.
- Colonization of the mouse intestine by an avirulent Salmonella typhimurium strain and its lipopolysaccharide-defective mutants.
- Phosphatidylserine found in intestinal mucus serves as a sole source of carbon and nitrogen for salmonellae and Escherichia coli.
- Expression of Escherichia coli F-18 type 1 fimbriae in the streptomycin-treated mouse large intestine.
- Characterization and identification of a porcine small intestine mucus receptor for the K88ab fimbrial adhesin.
- A Salmonella typhimurium mutant unable to utilize fatty acids and citrate is avirulent and immunogenic in mice.
- Role of leuX in Escherichia coli colonization of the streptomycin-treated mouse large intestine.
- Escherichia coli F-18 phase locked ''on'' for expression of type 1 fimbriae is a poor colonizer of the streptomycin-treated mouse large intestine.
- Construction of stable cloning vectors that do not segregate from a human fecal Escherichia coli strain in the streptomycin-treated mouse large intestine.
- Escherichia coli F-18 makes a streptomycin-treated mouse large intestine colonization factor when grown in nutrient broth containing glucose.
- In vivo colonization of the mouse large intestine and in vitro penetration of intestinal mucus by an avirulent smooth strain of Salmonella typhimurium and its lipopoly...
- The Escherichia coli K-12 gntP gene allows E. coli F-18 to occupy a distinct nutritional niche in the streptomycin-treated mouse large intestine.
- Roles of motility, chemotaxis, and penetration through and growth in intestinal mucus in the ability of an avirulent strain of Salmonella typhimurium to colonize the l...
- Type 1 pili are not necessary for colonization of the streptomycin-treated mouse large intestine by type 1-piliated Escherichia coli F-18 and E. coli K-12.
- Escherichia coli F-18 and E. coli K-12 eda mutants do not colonize the streptomycin-treated mouse large intestine.
- Colonization of the streptomycin-treated mouse large intestine by a human fecal Escherichia coli strain: role of adhesion to mucosal receptors.
- Neither motility nor chemotaxis plays a role in the ability of Escherichia coli F-18 to colonize the streptomycin-treated mouse large intestine.
- Utilization of the mouse large intestine to select an Escherichia coli F-18 DNA sequence that enhances colonizing ability and stimulates synthesis of type 1 fimbriae.
- Colonization of the streptomycin-treated mouse large intestine by a human fecal Escherichia coli strain: role of growth in mucus.
- A functional cra gene is required for Salmonella enterica serovar typhimurium virulence in BALB/c mice.
- Lysophosphatidic acid inhibition of the accumulation of Pseudomonas aeruginosa PAO1 alginate, pyoverdin, elastase and LasA.
Schools
Indiana University School Of Medicine
Meth Hospital
Doctors Specialties
- Family Medicine
- Emergency Medicine
Accepted Insurances
- Aetna
- American Republic
- Assurant Health
- CHAMPVA
- Great West Healthcare-Cigna PPO
- Commercial Insurance Company
- Coventry Health Care
- Emblem Health
- GEHA
- Medicare Advantage PFFS
- HealthSmart
- Humana
- MedHealthInsurance
- Medicaid
- Medical Mutual of Ohio
- Medicare MCR
- Medico
- Meritain Health
- Mutual of Omaha
- NGS CoreSource
- Planned Administration Inc
- Providence Health Plans
- Sagamore Plus
- Tricare
- UniCare
- United Healthcare
- Universal American
Drug Facts
| NPI NUMBER | 1538265301 | |
| NPPES Provider LastName | LAUX | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 478042706 | |
| NPPES Provider State | IN | |
| Specialty Description | Emergency Medicine | |
| Total Claim Count | 222.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 67.0 | |
| Percent Opioid Claims | 30.18 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1538265301 |
| Last Name Of The Provider | LAUX |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. James R. Buechler, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven Macke, MD
This Doctor is OpenDoctor Recommended.
|